Alembic Pharma

Alembic Pharma hit a new 52-week high after its Q2 numbers were declared. The company, led by a smart spike up in its export sales, posted a stellar set of numbers for Q2FY14, with standalone net profit coming at Rs.64 crore, up 56% (YoY) and up 31% sequentially. Net sales came in at Rs.485 crore, up 19% (YoY). Domestic sales at Rs.286 crore, was down 10% but exports rose by a smart 69% at Rs.200 crore.

On a consolidated basis, net sales rose 20% at Rs.488 crore and net profit rose 45% at Rs.62 crore. Here too, it was exports which was the star maker. R&D expenses have spiked up over 112% (YoY). Interest outgo remains small at around Rs.2 crore levels. EBITDA was up 19% at Rs.93 crore. EBITDA margin came in at a very healthy 19% v/s 15.9% (YoY).

Its international generic formulation sales rose 123% and domestic branded formulations were up 10%. As per ORG IMS, Alembic has maintained market share at 1.78%. Its speciality segment grew 24% though acute segment remained status quo. During the quarter, 2 ANDA applications were filed, taking the total tally to 59. During the quarter, it received one ANDA approval, taking the total approval tally to 30, which also includes 4 tentative approvals.